Pulmonary arterial hypertension: Pathobiology, diagnosis, treatment, and emerging therapies

Cardiology in Review

Volumn 18, Issue 2, 2010, Pages 58-63

  Rosenblum, Warren D ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

Author keywords

Endothelin receptor antagonists; Phosphodiesterase 5 inhibitors; Prostacyclin; Pulmonary hypertension; Right heart failure

Indexed keywords

AMBRISENTAN; AMLODIPINE; BONE MORPHOGENETIC PROTEIN; BOSENTAN; DEXFENFLURAMINE; DIGOXIN; DILTIAZEM; DIURETIC AGENT; ENDOTHELIN 1; FENFLURAMINE; ILOPROST; INOTROPIC AGENT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NIFEDIPINE; NITRIC OXIDE; POTASSIUM CHANNEL; PROSTACYCLIN; SEROTONIN; SILDENAFIL; SITAXSENTAN; TADALAFIL; UNIPROST; VASOACTIVE INTESTINAL POLYPEPTIDE; WARFARIN;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANTIHYPERTENSIVE THERAPY; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLOOD PRESSURE REGULATION; BLOOD VESSEL REACTIVITY; CATHETER INFECTION; CLINICAL FEATURE; CLINICAL TRIAL; COMPUTED TOMOGRAPHIC ANGIOGRAPHY; COUGHING; DISEASE COURSE; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG INDUCED HEADACHE; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY MONITORING; FLUSHING; GASTROINTESTINAL SYMPTOM; HEART DEATH; HEART RIGHT VENTRICLE FAILURE; HEART RIGHT VENTRICLE HYPERTROPHY; HUMAN; HYPERTROPHY; HYPERVOLEMIA; HYPOXEMIA; LUNG VASCULAR RESISTANCE; MONOTHERAPY; NONHUMAN; NOSE CONGESTION; OXYGEN THERAPY; PAIN; PATHOPHYSIOLOGY; PERIPHERAL EDEMA; PREVALENCE; PULMONARY ARTERY OCCLUSION; PULMONARY HYPERTENSION; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SIGNAL TRANSDUCTION; THORAX RADIOGRAPHY; THROMBOCYTOPENIA; THROMBOSIS; UNSPECIFIED SIDE EFFECT; VASCULAR ENDOTHELIUM;

BLOOD PRESSURE; CARDIOTONIC AGENTS; DIURETICS; ENDOTHELIN-1; EPOPROSTENOL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; NITRIC OXIDE; OXYGEN INHALATION THERAPY; PHOSPHODIESTERASE 5 INHIBITORS; PROSTAGLANDINS; RECEPTORS, ENDOTHELIN; RISK FACTORS; SEROTONIN; VASOACTIVE INTESTINAL PEPTIDE;

EID: 77149129287     PISSN: 10615377     EISSN: None     Source Type: Journal    
DOI: 10.1097/CRD.0b013e3181cd2c9e     Document Type: Review

References (38)

1. Gaine SP, Rubin LJ. Primary pulmonary hypertension. Lancet. 1998;352: 719-725.
2. Barst RJ, McGoon M, Torbicki A, et al. Diagnosis and differential assessment of pulmonary hypertension. J Am Coll Cardiol. 2004;43:40S-47S.
3. Rich S. Primary Pulmonary Hypertension: Executive Summary From the World Symposium on Primary Pulmonary Hypertension. Evian, France: World Health Organization; 1998.
4. Peacock AJ. Treatment of pulmonary hypertension. BMJ. 2003;326:835-836.
5. D'Alonzo DO, Barst RJ, Ayres SM. Survival in patients with PPH: results from a national prospective registry. Ann Int Med. 1991;115:343-349.
6. Wigley FM, Lima JA, Mayes M, et al. The prevalence of undiagnosed pulmonary arterial hypertension in subjects with connective tissue disease at the secondary health care level of community-based rheumatologists (the UNCOVER study). Arthritis Rheum. 2005;52:2125-2132.
7. Koh ET, Lee P, Gladman DD, et al. Pulmonary hypertension in systemic sclerosis: an analysis of 17 patients. Br J Rheumatol. 1996;35:989-993.
8. Vongpatanasin W, Brickner M, Hillis LD, et al. The Eisenmenger Syndrome in adults. Ann Intern Med. 1998;128:745-755.
9. Cappola TP, Felker GM, Kao WH, et al. Pulmonary hypertension and risk of death in cardiomyopathy. Circulation. 2002;105:1663-1668.
10. Krowka MJ. Hepatopulmonary syndromes. Gut. 2000;46:1-4.
11. Newman JH, Fanburg BL, Archer SL, et al. Pulmonary arterial hypertension: future directions: reports of a National Heart, Lung and Blood Institute/Office of Rare Disease Workshop. Circulation. 2004;109:2947-2952.
12. Lepetit H, Eddahibi S, Fadel E, et al. Smooth muscle cell matrix metalloproteinases in idiopathic pulmonary arterial hypertension. Eur Respir J. 2005; 25:834-842.
13. Begnini A, Remuzzi G. Endothelin antagonists. Lancet. 1999;353:133-138.
14. Giaid A, Yanagisawa M, Langleben D, et al. Expression of endothelin-1in the lungs of patients of pulmonary hypertension. N Engl J Med. 1993;328:1732-1739.
15. Stewart DJ, Levy RD, Cernacek P, et al. Increase plasma endothelin-1 in pulmonary hypertension: marker or mediator of disease? Ann Intern Med. 1991;114:464-469.
16. Tuder RM, Cool CD, Geraci MW, et al. Prostacyclin synthase expression is decreased in lungs from patients with severe pulmonary hypertension. Am J Respir Crit Care Med. 1999;159:1925-1932.
17. Cristman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med. 1992;237:70-75.
18. Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med. 1993;333: 214-221.
19. Cella G, Bellotto F, Toma F, et al. Plasma markers of endothelial dysfunction in pulmonary hypertension. Chest. 2001;120:1226-1230.
20. Lincoln TM. Cyclic GMP and phosphodiesterase 5 inhibitor therapies: what's on the horizon? Mol Pharmacol. 2004;66:11-13.
21. Eddahibbi S, Humbert M, Fadel E, et al. Serotonin transporter overexpression is responsible for pulmonary artery smooth muscle hyperplasia in primary pulmonary hypertension. J Clin Invest. 2001;108:1141-1150.
22. Guignabert C, Izikki M, Ieng L, et al. Transgenic mice overexpressing the 5-Hydroxytryptamine transporter gene in smooth muscle develop pulmonary hypertension. Circ Res. 2006;98:1323-1330.
23. Petkov V, Mosgeoller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest. 2003;111:1339-1346.
24. Eddahibbi S, Morrell N, d'Ortho M-P, et al. Pathobiology of pulmonary arterial hypertension. Eur Respir J. 2002;20:1559-1572.
25. Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension updated ACCP evidence-based clinical practice guidelines. Chest. 2007;131:1917-1928.
26. Rich S. Primary pulmonary hypertension. Prog Cardiovasc Dis. 1988;31: 205-238.
27. Rich S, Kaufman E, Levy PS. The effect of high doses of calcium-channel blockers in survival in primary pulmonary hypertension. N Engl J Med. 1992;327:76-81.
28. Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002;346:896-903.
29. Galiè N, Olschewski H, Oudiz RJ, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blinded, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation. 2008;117:3010-3019.
30. Barst RJ, Langleben D, Frost A, et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med. 2004;169:441-447.
31. Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin: a receptor antagonist sitaxsentan. J Am Coll Cardiol. 2006;47:2049-2056.
32. Galie N, Ghofrani HA, Torbicki A, et al. Sildenafil citrate therapy for pulmonary arterial hypertension. N Engl J Med. 2005;353:2148-2157.
33. Rubin LJ, Badesch D, Fleming T, et al. Long-term treatment with sildenafil citrate in pulmonary arterial hypertension. Chest. 2008;134:40003S.
34. Galiè N, Brudage BH, Ghofrani HA, et al. Tadalafil therapy for pulmonary hypertension. Circulation. 2009;119:2894-2903.
35. Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (Prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med. 1996;334:296-301.
36. Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil a prostacyclin analogue, in patients with pulmonary artery hypertension. Am J Respir Crit Care Med. 2002;165:800-804.
37. McLaughlin V, Oudiz RJ, Frost A, et al. Randomized study of adding inhaled iloprost to existing bosentan in pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006;174:1257-1263.
38. Simonneau G, Rubin LJ, Galiè N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension. Ann Int Med. 2008;149:521-530.